| PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement AB Khan, SF Barrington, NG Mikhaeel, AA Hunt, L Cameron, T Morris, ... Blood, The Journal of the American Society of Hematology 122 (1), 61-67, 2013 | 275 | 2013 |
| Molecular MRD status and outcome after transplantation in NPM1-mutated AML R Dillon, R Hills, S Freeman, N Potter, J Jovanovic, A Ivey, AS Kanda, ... Blood, The Journal of the American Society of Hematology 135 (9), 680-688, 2020 | 148 | 2020 |
| Redirection to the bone marrow improves T cell persistence and antitumor functions AB Khan, B Carpenter, PS e Sousa, C Pospori, R Khorshed, J Griffin, ... The Journal of clinical investigation 128 (5), 2010-2024, 2018 | 44 | 2018 |
| Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome-UK experience A Al-Hakim, JA Poulter, D Mahmoud, AMS Rose, S Elcombe, ... British journal of haematology 199 (5), 777-781, 2022 | 39 | 2022 |
| Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study MH Albert, T Sirait, DJ Eikema, K Bakunina, C Wehr, F Suarez, ML Fox, ... Blood, The Journal of the American Society of Hematology 140 (14), 1635-1649, 2022 | 34 | 2022 |
| Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy J Othman, IS Tiong, J O'Nions, M Dennis, K Mokretar, A Ivey, M Austin, ... Blood 143 (4), 336-341, 2024 | 29 | 2024 |
| Staging DLBCL: bone marrow biopsy or PET-CT? A Avigdor Blood, The Journal of the American Society of Hematology 122 (1), 4-5, 2013 | 22 | 2013 |
| FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML J Othman, N Potter, K Mokretar, D Taussig, A Khan, P Krishnamurthy, ... Leukemia 37 (10), 2066-2072, 2023 | 21 | 2023 |
| Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and … PDE Miller, SR Patel, R Skinner, F Dignan, A Richter, K Jeffery, A Khan, ... Journal of Infection 86 (1), 1-8, 2023 | 19 | 2023 |
| Let off the leash: kala-azar following the use of tumour necrosis factor antibodies A Khan, G Coakley, C Cosgrove, D Lockwood Case Reports 2010, bcr0420102878, 2010 | 19 | 2010 |
| Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from … P Ljungman, G Tridello, JL Piñana, F Ciceri, H Sengeloev, A Kulagin, ... Frontiers in immunology 14, 1125824, 2023 | 16 | 2023 |
| Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT C Gurnari, L Koster, L Baaij, M Heiblig, I Yakoub-Agha, M Collin, ... Blood Advances 8 (6), 1444-1448, 2024 | 15 | 2024 |
| Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting MAV Marzolini, V Mehra, KJ Thomson, E Tholouli, AJC Bloor, A Parker, ... Blood advances 5 (21), 4500-4503, 2021 | 9 | 2021 |
| A descriptive study of the characteristics of older adults with sickle cell disease AB Khan, R Kesse‐Adu, C Breen, PB Murphy, J Chambers, P Holmes, ... American journal of hematology 93 (2), E38-E40, 2018 | 9 | 2018 |
| Hypoplastic MDS is a distinct clinico-pathological entity with somatic mutations frequent in patients with prior aplastic anaemia with favorable clinical outcome AA Hunt, AB Khan, VT Potter, D McLornan, K Raj, H de Lavallade, ... Blood 124 (21), 3269, 2014 | 8 | 2014 |
| High molecular response rate and overall survival with FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in AML J Othman, N Potter, K Mokretar, D Taussig, A Khan, P Krishnamurthy, ... Blood 140 (Supplement 1), 2002-2004, 2022 | 6 | 2022 |
| Venetoclax with azacitidine or low dose cytarabine as an alternative to intensive chemotherapy in fit adults during the COVID19 pandemic: real world data from the UK National … J Othman, M Amer, R Amofa, L Anderson, MJ Austin, A Bashford, ... Blood 138 (Supplement 1), 2321-2321, 2021 | 5 | 2021 |
| Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma V Noriega, H Kaur, S Devereux, J Byrne, R Marcus, A Haynes, D Yallop, ... Leukemia Research 38 (7), 737-743, 2014 | 5 | 2014 |
| Venetoclax-based non-intensive combinations successfully salvage molecular relapse of acute myeloid leukemia and are an important bridge to cellular therapy in relapsed … H Wood, C Bourlon, A Kulasekararaj, A Borg, J Pavlu, P Elder, ... Blood 140 (Supplement 1), 9016-9018, 2022 | 4 | 2022 |
| Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service J Othman, U Afzal, R Amofa, MJ Austin, A Bashford, E Belsham, J Byrne, ... Blood 138 (Supplement 1), 1254-1254, 2021 | 3 | 2021 |
Tim P MorrisMRC Clinical Trials Unit at UCLVerified email at ucl.ac.uk